• NewcelX entered agreements for a $1.55 million private placement at $3.29 per share.
• The sale comprises 471,125 common shares, priced at a 20% premium to the November 6, 2026, closing price.
• One series of warrants covers 353,344 common shares at an exercise price of $3.75 per share.
• Closing is expected on or about November 23, 2026, subject to customary conditions.
• Proceeds will primarily advance diabetes program NCEL-101, supporting IND-enabling studies and preparations for a planned Phase 1/2a trial in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090900PRIMZONEFULLFEED9873203) on November 09, 2026, and is solely responsible for the information contained therein.